Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) has shared an update.
Shanghai Bio-heart Biological Technology Co., Ltd. has initiated its SAKURA-SCB clinical trial in Japan, enrolling the first patient to evaluate a new sirolimus drug-coated balloon (DCB) for ischemic heart disease. This product aims to offer a safer alternative to existing paclitaxel-based treatments by utilizing sirolimus for its anti-inflammatory and cytostatic effects, potentially improving therapeutic outcomes and reducing restenosis.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-heart Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on developing medical technologies for cardiovascular diseases. The company specializes in creating innovative products like drug-coated balloons for treating heart conditions, with a market focus on enhancing treatment efficacy and safety.
YTD Price Performance: 82.32%
Average Trading Volume: 324,494
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.25B
For an in-depth examination of 2185 stock, go to TipRanks’ Stock Analysis page.